Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kenneth E Ugen, Xiaoyang Lin, Ge Bai, Zhanhua Liang, Jianfeng Cai, Kunyun Li, Shijie Song, Chuanhai Cao & Juan Sanchez-Ramos. (2015) Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. Human Vaccines & Immunotherapeutics 11:4, pages 922-930.
Read now
Read now
Articles from other publishers (26)
Lidia Gatto, Vincenzo Di Nunno, Alicia Tosoni, Stefania Bartolini, Lucia Ranieri & Enrico Franceschi. (2023) DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open. Cancers 15:12, pages 3251.
Crossref
Crossref
Andrea Franson, Brandon L. McClellan, Maria Luisa Varela, Andrea Comba, Mohammad Faisal Syed, Kaushik Banerjee, Ziwen Zhu, Nazareno Gonzalez, Marianela Candolfi, Pedro Lowenstein & Maria Graciela Castro. (2022) Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment. Frontiers in Medicine 9.
Crossref
Crossref
Angeliki Datsi & Rüdiger V. Sorg. (2021) Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. Frontiers in Immunology 12.
Crossref
Crossref
Alexander F Haddad, Jacob S Young, Dominic Amara, Mitchel S Berger, David R Raleigh, Manish K Aghi & Nicholas A Butowski. (2021) Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neuro-Oncology Advances 3:1.
Crossref
Crossref
Fiona A. Desland & Adília Hormigo. (2020) The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy. International Journal of Molecular Sciences 21:19, pages 7358.
Crossref
Crossref
Syreeta DeCordova, Abhishek Shastri, Anthony G. Tsolaki, Hadida Yasmin, Lukas Klein, Shiv K. Singh & Uday Kishore. (2020) Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma. Frontiers in Immunology 11.
Crossref
Crossref
Marion Rapp, Oliver M. Grauer, Marcel Kamp, Natalie Sevens, Nikola Zotz, Michael Sabel & Rüdiger V. Sorg. (2018) A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials 19:1.
Crossref
Crossref
V. Chandramohan, L. Sanchez-Perez, Y. He, C.J. Pirozzi, K.L. Congdon & D.D. Bigner. 2017. Translational Immunotherapy of Brain Tumors. Translational Immunotherapy of Brain Tumors
111
147
.
Lingyan Lv, Yan Jiang, Xin Liu, Baoyan Wang, Wei Lv, Yue Zhao, Huihui Shi, Quanyin Hu, Hongliang Xin, Qunwei Xu & Zhen Gu. (2016) Enhanced Antiglioblastoma Efficacy of Neovasculature and Glioma Cells Dual Targeted Nanoparticles. Molecular Pharmaceutics 13:10, pages 3506-3517.
Crossref
Crossref
Gaetano Finocchiaro & Serena Pellegatta. (2015) Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies. Cancer Immunology, Immunotherapy 65:1, pages 101-109.
Crossref
Crossref
Sara Nava, Daniela Lisini, Simona Pogliani, Marta Dossena, Anna Bersano, Serena Pellegatta, Eugenio Parati, Gaetano Finocchiaro & Simona Frigerio. (2015) Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients. Stem Cells Translational Medicine 4:10, pages 1164-1172.
Crossref
Crossref
Angela Vasaturo, Martijn Verdoes, Jolanda de Vries, Ruurd Torensma & Carl G. Figdor. (2015) Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment. Immunobiology 220:2, pages 243-248.
Crossref
Crossref
Veronica Catalano, Cecilia Eleuteri, Gaia Campoccia, Gianluca Giacobini, Mariangela Zane, Giorgio Stassi, Giorgio Parmiani & Cristina Maccalli. 2015. Resistance of Cancer Cells to CTL-Mediated Immunotherapy. Resistance of Cancer Cells to CTL-Mediated Immunotherapy
3
29
.
Taemin Oh, Shayan Fakurnejad, Eli T Sayegh, Aaron J Clark, Michael E Ivan, Matthew Z Sun, Michael Safaee, Orin Bloch, Charles D James & Andrew T Parsa. (2014) Immunocompetent murine models for the study of glioblastoma immunotherapy. Journal of Translational Medicine 12:1, pages 107.
Crossref
Crossref
S. de Chickera, C. Willert, C. Mallet, R. Foley, P. Foster & G. A. Dekaban. (2011) Cellular MRI as a suitable, sensitive non-invasive modality for correlating in vivo migratory efficiencies of different dendritic cell populations with subsequent immunological outcomes. International Immunology 24:1, pages 29-41.
Crossref
Crossref
Wim Maes & Stefaan W. Van Gool. (2010) Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunology, Immunotherapy 60:2, pages 153-160.
Crossref
Crossref
Hilko Ardon, Steven De Vleeschouwer, Frank Van Calenbergh & Stefaan W. Van Gool. 2011. Tumors of the Central Nervous System, Volume 2. Tumors of the Central Nervous System, Volume 2
313
333
.
Won Kim & Linda M. Liau. (2010) Dendritic Cell Vaccines for Brain Tumors. Neurosurgery Clinics of North America 21:1, pages 139-157.
Crossref
Crossref
Jin He, Yi Yin, Troy A. Luster, Linda Watkins & Philip E. Thorpe. (2009) Antiphosphatidylserine Antibody Combined with Irradiation Damages Tumor Blood Vessels and Induces Tumor Immunity in a Rat Model of Glioblastoma. Clinical Cancer Research 15:22, pages 6871-6880.
Crossref
Crossref
Stefaan Van Gool, Wim Maes, Hilko Ardon, Tina Verschuere, Sofie Van Cauter & Steven De Vleeschouwer. (2009) Dendritic Cell Therapy of High-Grade Gliomas. Brain Pathology 19:4, pages 694-712.
Crossref
Crossref
W. Maes, C. Deroose, V. Reumers, O. Krylyshkina, R. Gijsbers, V. Baekelandt, J. Ceuppens, Z. Debyser & S. W. Van Gool. (2008) In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma. Journal of Neuro-Oncology 91:2, pages 127-139.
Crossref
Crossref
Paul R. Walker, Robert M. Prins, Pierre-Yves Dietrich & Linda M. Liau. 2009. CNS Cancer. CNS Cancer
1165
1217
.
S Sas, T Chan, A Sami, A El-Gayed & J Xiang. (2008) Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice. Cancer Gene Therapy 15:10, pages 655-666.
Crossref
Crossref
Oliver M. Grauer, Roger P.M. Sutmuller, Wendy van Maren, Joannes F.M. Jacobs, Erik Bennink, Liza W.J. Toonen, Stefan Nierkens & Gosse J. Adema. (2007) Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. International Journal of Cancer 122:8, pages 1794-1802.
Crossref
Crossref
Apostolos Stathopoulos, Christian Samuelson, Germain Milbouw, Jean Philippe Hermanne, Virgil E. J.C. Schijns & Thomas C. Chen. (2008) Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat. Vaccine 26:14, pages 1764-1772.
Crossref
Crossref
Gustavo A. Moviglia, Antonio G. Carrizo, Gabriela Varela, Carlos A. Gaeta, Andrea Paes de Lima, Pablo Farina & Hugo Molina. (2008) Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme. Hematology/Oncology and Stem Cell Therapy 1:1, pages 3-13.
Crossref
Crossref